U.S. Markets closed

FDA puts clinical hold on Advaxis cancer drug

Oct 6 (Reuters) - Advaxis Inc said the U.S. Food and Drug Administration has put on hold the clinical trials of its experimental cancer drug after a patient died.

The clinical hold on the drug, axalimogene filolisbac, was issued after Advaxis submitted a safety report to the FDA, the company said on Tuesday.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian)